Guselkumab: First Global Approval MarkhamAnthony 2018 <div>Compliance with Ethical Standards</div><div><br></div><div><i>Funding: </i>The preparation of this review was not supported by any external funding.</div><div><br></div><div><i>Conflicts of interest</i>: Anthony Markham is a contracted employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.</div><div><br></div><div>Additional information about this Adis Drug Review can be found <b><a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews">here</a>.</b></div><div><br></div><div>Abstract</div><div><br></div><div>Guselkumab (TREMFYA™) is a human monoclonal IgG1λ antibody being developed by Janssen Biotech, Inc. that has been approved in the USA as a treatment for moderate-to-severe plaque psoriasis. Guselkumab inhibits the binding of interleukin 23 (IL-23), disrupting the type 17 helper T cell/IL-17 pathway. This article summarizes the milestones in the development of guselkumab leading to this first approval for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Access to the full article can be found <a href="https://link.springer.com/article/10.1007/s40265-017-0800-7"><b>here</b></a>.</div><div><br></div><div>© Springer International Publishing AG, part of Springer Nature 2017</div>